arrow
K

Kevin E. Yarasheski

c2n diagnostics
H指数:72
被引数:2.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The AlzMatch Pilot Study - Feasibility of Remote Blood Collection of Plasma Biomarkers for Preclinical Alzheimer's Disease Trials
2024-10-010
PRE
PrecivityAD2™ Blood Test: Analytical Validation of an LC-MS/MS Assay for Quantifying Plasma Phospho-tau217 and Non-Phospho-tau217 Peptide Concentrations That Are Used with Plasma Amyloid-β42/40 in a Multianalyte Assay with Algorithmic Analysis for Detecting Brain Amyloid Pathology
2024-08-100
OAAI
Unexpected Low Rate of Amyloid-β Pathology in Multiple Sclerosis Patients
2024-07-043
PRE
Racial and ethnic differences in plasma biomarker eligibility for a preclinical Alzheimer's disease trial

临床前阿尔茨海默病试验的血浆生物标志物资格的种族和种族差异

2024-04-174
OA
Sensitivity of the African neuropsychology battery memory subtests and learning slopes in discriminating APOE 4 and amyloid pathology in adult individuals in the Democratic Republic of Congo
2024-03-271
OAAI
Clinical validation of the PrecivityAD2 blood test: A mass spectrometry-based test with algorithm combining %p-tau217 and Aβ42/40 ratio to identify presence of brain amyloid
2024-03-1615
OA
The Association of Alzheimer's Disease-Related Blood-Based Biomarkers with Cognitive Screening Test Performance in the Congolese Population in Kinshasa

在金沙萨的刚果人群中,阿尔茨海默氏病相关的基于血液的生物标志物与认知筛查测试性能的关联

2024-01-304
OA
Associations of sleep duration and daytime sleepiness with plasma amyloid beta and cognitive performance in cognitively unimpaired, middle-aged and older African Americans
SLEEP
IF4.9
2023-11-272
PRE
Association of plasma biomarkers with cognitive function in persons with dementia and cognitively healthy in the Democratic Republic of Congo
2023-11-081
OAAI
Plasma Aß42/Aß40 and phospho-tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer's disease
2023-11-0636
OA
Plasma Aβ42/40 and cognitive variability are associated with cognitive function in Black Americans: Findings from the AA-FAIM cohort
2023-09-251
OA
Evaluation of Blood-Based Plasma Biomarkers as Potential Markers of Amyloid Burden in Preclinical Alzheimer's Disease

评估基于血液的血浆生物标志物作为临床前阿尔茨海默病淀粉样蛋白负荷的潜在标志物

2023-03-079
OAAI
Effect of Race on Prediction of Brain Amyloidosis by Plasma Aβ42/Aβ40, Phosphorylated Tau, and Neurofilament Light
2022-07-1986
OAAI
Assessment of a Plasma Amyloid Probability Score to Estimate Amyloid Positron Emission Tomography Findings Among Adults With Cognitive Impairment
2022-04-2161
OAAI
A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis

结合血浆Aβ42/40比率,ApoE蛋白质型和年龄的基于血液的诊断测试可准确识别脑淀粉样蛋白状态: 多队列有效性分析的结果

2021-05-01132
OAAI